Efficacy of Cardioviva™ Probiotic Yogurt Formulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Micropharma Limited
ClinicalTrials.gov Identifier:
NCT01185795
First received: August 18, 2010
Last updated: June 29, 2012
Last verified: June 2012

August 18, 2010
June 29, 2012
September 2008
January 2009   (final data collection date for primary outcome measure)
The primary outcome variable will be the percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01185795 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Cardioviva™ Probiotic Yogurt Formulation
Efficacy of a Microencapsulated Probiotic Yogurt Formulation as a Health Promoting Agent

Background: Several studies have reported limited or no reduction in serum lipid concentrations in response to probiotic formulations. More recently, probiotics have shown promise in treating metabolic disease, due to improved strain selection and delivery technologies.

Objective: To evaluate the lipid lowering efficacy of a yogurt formulation containing microencapsulated Bile Salt Hydrolase (BSH)-active Lactobacillus reuteri cardioviva, taken twice per day over 6 weeks, in subjects with hypercholesterolemia.

Design: This is a double-blinded, multi-centric, placebo-controlled, randomized, parallel-arm study. The study will last a total of 10 weeks including 2-week wash-out, 2-week run-in, and 6- week treatment period.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypercholesterolemia
  • Dietary Supplement: Cardioviva™ yogurt
    L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
  • Dietary Supplement: Placebo yogurt
    yogurt, twice per day (BID), 6 weeks
  • Experimental: Cardioviva™ yogurt
    Intervention: Dietary Supplement: Cardioviva™ yogurt
  • Placebo Comparator: Placebo yogurt
    Intervention: Dietary Supplement: Placebo yogurt
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
April 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males and females.
  • Aged 18-74 years old.
  • Low Density Lipoprotein (LDL-C) above 3.4 mmol/L (<15% variation between visits V1 and V2-1).
  • Triglyceride (TG) levels below 4.0 mmol/l (check at V0 and V2-1).
  • Body Mass Index (BMI) range was 22 to 32 kg/m2.
  • Ability to understand dietary procedures.
  • Judged by the investigators as compliant (>80%) with product consumption (check at V2-1), and motivated.
  • Signed informed consent form prior to inclusion in the study
  • Note: Subjects were permitted to take stable doses of thyroid hormone, anti-hypertensive agents, and contraceptive hormones (e.g. contraceptive pills or patches), as long as these were continued equivalently throughout the duration of study.

Exclusion Criteria:

  • Use of statin or other cholesterol lowering prescription drugs within the last 6 months.
  • Use of plant sterols, omega-3, fish oil, soy protein, soluble oat fiber, psyllium seed husk, or other cholesterol lowering non-prescription supplements within last 3 months.
  • History of chronic use of alcohol (>2 drinks/day).
  • Use of systemic antibodies, corticosteroids, androgens, or phenytoin.
  • Myocardial infarction, coronary artery bypass, or other major surgical procedures within the last six months.
  • Lactose intolerance or allergies to dairy products.
  • History of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, diabetes, gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year).
  • Chronic user of probiotics or fiber laxative (greater than 2 doses/week), or stimulant laxatives.
  • History of eating disorders.
  • Exercise greater than 15 miles/week or 4,000 kcal/week.
  • Pregnancy, breast feeding, or intent to get pregnant.
Both
18 Years to 74 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01185795
MP-001
No
Micropharma Limited
Micropharma Limited
Not Provided
Study Director: Mitchell L Jones, MD, MEng Micropharma Limited
Micropharma Limited
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP